Globus Medical Stock Plunges 8.48% After Sales Forecast Cut — Erasing $928 Million
Management blamed launch delays and weak recruiting for the sales cut, while keeping its adjusted earnings outlook unchanged.
Globus Medical, which develops and sells medical devices for musculoskeletal disorders, plunged 8.48% to $74.53 in Friday trading, as of 10:03 a.m. ET, erasing $928 million in market value after Thursday's sales forecast cut. The company reduced its 2026 revenue outlook to $3.09 billion, while leaving its adjusted earnings forecast intact.
Launch Delays, Not Market Conditions
The new sales target replaces a range of $3.18 billion to $3.22 billion, according to the company's Thursday SEC filing. The unchanged forecast: $4.95 to $5.05 per share in adjusted earnings.
On Thursday's earnings call, Globus Medical President and CEO Keith Pfeil attributed the reduction to delayed product launches and weak recruiting of sales representatives, rather than market conditions. Management's explanation put the sales shortfall within the company's own operations.
Sales Fell With Nevro Included
A 0.7% reported decline, or 0.5% excluding currency effects, left third-quarter total sales at $763.7 million. Excluding Nevro, sales rose 3% to $690.0 million.
The Audubon, Pennsylvania-based company supplies hospitals, ambulatory surgery centers and surgeons. Its products range from implants, biologics and surgical instruments to spinal cord stimulation therapy and nerve-monitoring services for spine, orthopedic and neurosurgical procedures.
Globus also sells surgical imaging, navigation and robotics systems. Sales are concentrated in the United States, where it uses its own sales representatives and those of exclusive independent distributors. International business accounted for about 19.4% of sales in 2025; as of December 31, 2025, it had a direct or distributor sales presence in 64 countries outside the United States.
A Slide From An Already-Weaker Stock
GMED entered Friday behind the market: at Thursday's close, the shares were down 7% year-to-date, while the S&P 500 had gained 8% over the same period.
Friday's decline left Globus Medical with a market value of $10.01 billion as of 10:03 a.m. ET.
In Friday trading, GMED was on pace for its biggest one-day decline in at least 275 trading sessions.
Sources
- Globus Medical lowers 2026 revenue outlook to $3.09B while reiterating non-GAAP EPS of $4.95-$5.05 (NYSE:GMED) | Seeking Alpha — seekingalpha.com
- Compared to Estimates, Globus Medical (GMED) Q3 Earnings: A Look at Key Metrics — Yahoo Finance
- Globus Medical (GMED) Q3 Earnings Top Estimates — Yahoo Finance
- Globus Medical: Q3 Earnings Snapshot | wusa9.com — Associated Press
- Globus Medical Non-GAAP EPS of $1.23 beats by $0.03, revenue of $763.7M misses by $28.76M (GMED:NYSE) | Seeking Alpha — seekingalpha.com
- The company's filing (Globus Medical) — SEC filing
- Globus Medical (GMED) Q3 Earnings Top Estimates — Zacks Investment Research
- Globus Medical — Form 10-Q for the quarter ended 2026-09-30 (quarterly results) — SEC EDGAR